Basem Goueli MD/PhD/MBA

CancerClarity

We are in our early stages in the development of CancerClarity, which is in the clinical trial, pharmaceutical consulting, cancer center consulting, and clinical treatment forums.  We are presently in stealth mode.

CEO and Founder

CancerLight

We are in the early stages of developing CancerLight, a company in the patient education space.  We are presently in stealth mode.

Catholic Health

Medical director of hematology/medical oncology for Catholic Health System.

Medical Director of Hematology/Medical Oncology

Great Lakes Cancer Care

Director of Hematology and Medical Oncology

University at Buffalo

Associate Chief of Hematology/Medical Oncology

Covenant Health/Thompson Oncology Group

St. Luke's Reginoal Cancer Center

Director

I have directed three independent cancer institutes, collectively representing 17 hospitals and 12 cancer centers.  I am a hematologist and medical oncologist who has been the institutional principal investigator on nearly 100 clinical trials involving breast cancer, myeloma, prostate cancer, lung cancer, melanoma, ovarian cancer, head and neck cancer, myelodysplastic syndrome, CLL, DLBCL, esophageal cancer, etc.  I was on three papers published in The New England Journal of Medicine (prostate cancer, chronic neutrophilic leukemia, lung cancer) and two in Lancet (Shingles vaccine and head and neck cancer).  I am board certified in hematology, medical oncology, internal medicine, and artificial intelligence in medicine.


As depicted in my profile, my training background includes:
MD:  Mayo Clinic
PhD in biochemistry:  Mayo Clinic
MBA:  University of North Carolina, Chapel Hill
Internal Medicine Residency:  George Washington University Hospital with 4 months at the NIH
Hematology/Oncology Clinical Fellowship:  Stanford
Biochemistry Post-Doctoral Fellowship:  Stanford
MIT Xpro Course Certificate:  Designing Artificial Intelligence Products 
MIT Xpro: Course Certificate:  Robotics Essentials 
MIT Xpro: Course Certificate:  Drug and Medical Device Development 
MIT Professional Education Course Certificate:  Applied Data Science Bootcamp

I resisted the trend towards subspecialization in my career as I feel ideation often happens at the level of the forest, not the trees.  Many of the greatest future innovations will be at the interface of various disciplines. 

My area of clinical expertise is precision medicine, and my ability to treat patients in all hematology/medical oncology disciplines uniquely positions me to sequence molecular-based therapies in the context of conventional therapy and clinical trials.

I am the CEO and Founder of three companies:  CancerClarity, CancerLight, and Revolution Cancer Medical Care PLLC.  We are early in our development as we hope to disrupt the clinical trial, patient education, and clinical care forums.  Aside from building my two companies, I am a consulting medical director for 2 phase 1 Xbiotech clinical trials (pancreatic cancer), consult for numerous other pharmaceutical companies, and see patients full-time in the clinic as a hematologist/medical oncologist.  I recently turned down several high-visibility positions to pursue my vision.

My singular focus is to help as many people as I can in the shortest time frame possible.

Daiichi Sankyo, Inc.

Associate Director, Market Access

Genentech

Senior Clinical Oncology Specialist- Hematology

Cephalon

Hospital Account Manager/Regional Field Based Trainer

My collaboration with oncology academic cancer account leadership in New England including, Upstate New York, is to build relationships and implement initiatives which provide solutions to complex healthcare challenges.

As Associate Director, I lead internal teams (commercial, medical, reimbursement, nurse educators, payer, marketing) for all pre launch strategies for our entire ADC and emerging asset oncology portfolio to Leadership, Quality, Clinical Research, Population Health Decision Makers, Pharmacy, Health Outcomes, Innovation teams.

My portfolio position allows me the privilege to interface collaboratively with C-Suite and key medical decision makers including KOL’s , within Academic, GPO’S, large IDN’s to remove barriers advancing the continuum of patient care with a strategic focus with pre launch information and health economics.  

Launches with DSI:
TDXD -breast - 2L, Her2 low, 3rd line
TDXD- GI, mutant NSCLC and compendia listings 
Injectafer- pediatric and heart failure
AML- Quizartinib AML

Pending launches - new asset in HER3 in lung and DATO-dxd.

I lead all contracting with GPO’s and Hospital/IDN’s for our portfolio.




Michelle Wardzinski MBA/MPH

taplio

The Battle

Basem Goueli MD/PhD/MBA

Michelle Wardzinski MBA/MPH

Followers

Posts

Engagements

Likes

Ready to grow your LinkedIn presence?